ReRouting biomedical innovation: observations from a mapping of the alternative research and development (R&D) landscape. [PDF]
Global Health, 2016 Greenberg A, Kiddell-Monroe R.
europepmc +1 more source
KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer
Molecular Oncology, EarlyView.Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan +16 more
wiley +1 more source
Learning, Internal Research, and Spillovers Evidence from a Sample of R&D Laboratories [PDF]
This paper presents new evidence on the practice of industrial Research and Development (R&D), especially the allocation between learning and internal research, and the role of outside knowledge, as represented by R&D spillovers, in reshaping this ...
James D. Adams
core
The mismatch between the health research and development (R&D) that is needed and the R&D that is undertaken: an overview of the problem, the causes, and solutions. [PDF]
Glob Health Action, 2013 Viergever RF.
europepmc +1 more source
Molecular Oncology, EarlyView.RNA profiling of circulating extracellular vesicles (EVs) from blood samples of men undergoing prostate biopsy identifies transcripts associated with clinically significant prostate cancer. Integrative analysis with public tumor datasets links EV‐derived gene signatures to tumor stage and progression‐free survival, highlighting CASP3, XRCC2, and RIT1 ...
Stefan Werner +14 more
wiley +1 more source
Industrial R&D Laboratories: Windows on Black Boxes? [PDF]
This paper provides an overview of the survey-based literature on industrial Research and Development (R&D) laboratories, beginning with the work of Edwin Mansfield.
James D. Adams
core
P15-03. HIV vaccine funding trends entering a global recession: research and development (R&D) from 2000 – 2008 [PDF]
Retrovirology, 2009 Fisher K +6 more
europepmc +1 more source
Molecular Oncology, EarlyView.This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska +13 more
wiley +1 more source
Molecular Oncology, EarlyView.Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura +19 more
wiley +1 more source
International collaborative research and development (R&D) on traditional medicine and its contextual factors: a cross-sectional analysis from 1996 to 2022. [PDF]
J Glob HealthSun Y +7 more
europepmc +1 more source